Zentalis

Zentalis : Discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor.

Sector/Industry:

Healthcare/Biotechnology

Characteristics:

Based in...

US - Middle Atlantic

Clinical Stage

Phase l or ll

Disease Space

Oncology

Listing

Public, USA

Market Cap

1B +

Website:

https://www.zentalis.com/

Profiles:

Address:

530 Seventh Avenue, Ste 2201
Corner of 39 St
New York, NY 10018
United States

Presentation:

Presentation at Solebury Trout Virtual Management Access Event 2021
Zentalis

Please reach out to Solebury Trout to request a presentation

More info:

Send Message to Request Information

My account:

Company Participants at Solebury Trout CEO & Investor Ski Conference 2020

Anthony Sun, CEO
Melissa Epperly, CFO

Lead Programs

ZN-c5: Oral SERD

oral selective estrogen receptor degrader (SERD)

Indication	Phase
Breast Cancer	1/2

ZN-c3: WEE1

oral inhibitor of WEE1

Indication	Phase
Solid Tumors	1/2

ZN-d5: BCL-2

oral selective inhibitor of B-cell lymphoma 2 (BCL-2)

Indication	Phase
Hematologic Malignancies	IND

ZN-e4: EGFR

oral, small molecule inhibitor of mutant epidermal growth factor receptor (EGFR)

Indication	Phase
NSCLC	1/2

Top 10 Holders of Zentalis Pharmaceuticals, Inc.

Institution	OS (%)	Position	Mkt Val ($MM)	Source	Filing Date
Viking Global Investors LP	10.99	3,943,284	170.43	Stakes	12/1/20
Matrix Capital Management Co. LP	10.65	3,821,739	165.18	13F	9/30/20
Fidelity Management & Research Co. LLC	7.95	2,850,720	123.21	13F	9/30/20
Tybourne Capital Management (HK) Ltd.	7.43	2,664,409	115.16	13F	9/30/20
Redmile Group LLC	6.78	2,432,408	105.13	13F	9/30/20
The Vanguard Group, Inc.	6.52	2,340,316	101.15	Funds	12/31/20
Citadel Advisors LLC	5.24	2,129,964	92.06	Stakes	4/3/20
Citadel LP	4.71	1,689,634	73.03	13F	9/30/20
PRIMECAP Management Co.	3.85	1,382,750	59.76	13F	9/30/20
Vanguard Group, Inc. (Subfiler)	3.09	1,109,753	47.96	13F	9/30/20

Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...

Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.